Here are the 10-K annual reports from Corcept Therapeutics Inc. (CORT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CORT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CORT filings page.
Corcept Therapeutics is a commercial-stage biopharma focused on diseases driven by the stress hormone cortisol, including hypercortisolism, several solid tumors, liver disease and ALS. It already markets Korlym and an authorized generic in the United States for Cushing’s syndrome–related hypercortisolism.
The company’s lead selective cortisol modulator, relacorilant, received an FDA Complete Response Letter for hypercortisolism despite positive GRACE and GRADIENT data, and Corcept is working with the agency on a new approval path. Relacorilant plus nab-paclitaxel showed meaningful progression-free and overall survival benefits in platinum‑resistant ovarian cancer, supporting U.S. and EU marketing applications with a PDUFA date of July 11, 2026. Corcept is also advancing selective modulators miricorilant for MASH, dazucorilant for ALS (with Fast Track and orphan status, and a planned Phase 3 in 2026), and nenocorilant in combination with immunotherapy, funded by increasing R&D spending across a broad pipeline.